# Europe Nucleic Acid Therapeutics Market > Europe Nucleic Acid Therapeutics Market Research Report Information By Products (Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others), By Application (Monogenetic Disorders and Multi-genetic Disorders), By End User (Hospitals and Clinics and Academic and Research Institutes) – and Europe Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.74% - **2024:** $ 156.18 Million - **2025:** $ 162.62 Million - **2035:** $ 233.87 Million - **Key Players:** Roche (CH), Novartis (CH), Sanofi (FR), Bayer (DE), AstraZeneca (GB), GSK (GB), BioNTech (DE), CureVac (DE), Genmab (DK) **Report ID:** MRFR/HC/11136-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/europe-nucleic-acid-therapeutics-market-12660 --- ## Market Summary ## **Europe Nucleic Acid Therapeutics Market Overview ** The nucleic acid therapeutics market industry is projected to grow from USD Significant by 2032, exhibiting a compound annual growth rate (CAGR) of moderate during the forecast period (2023 - 2032). Nucleic acid therapeutics market growth has been driven by several key market drivers, including the creation of biological products, DNA therapies, and the growth of the pharmaceutical and healthcare sectors. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Nucleic Acid Therapeutics Market Trends** ### **Growing concern about the use of nucleic acid therapies to address hereditary and chronic conditions is driving the market growth** The potential of nucleic acid medicines to cure hereditary and chronic illnesses is driving up demand for them. DNA and RNA are examples of nucleic acids, which are vital molecules that are crucial for controlling gene expression and protein synthesis in cells. Furthermore, market growth will be fueled by an increase in the number of nucleic acid therapies approved by the FDA or the European Medicines Agency (EMA). In recent years, there has been a notable surge in the approval and development of nucleic acid medicines, encompassing RNA and DNA-based treatments. Technology advancements and our growing understanding of the genetic pathways behind many diseases are partly to blame for this. For example, Onpattro (patisiran), a small interfering RNA (siRNA) therapy, has been approved as a nucleic acid therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR). The FDA approved this treatment for RNA interference (RNAi) for the first time in 2018. CDMOs can use a number of recent developments in manufacturing technology to increase productivity and cut expenses. The application of continuous manufacturing techniques is one such development. Instead of batch processing, which can be labor-intensive and need a large quantity of equipment, this method runs reactions in a continuous flow. Large amounts of starting materials and reagents are not required as frequently in continuous manufacturing, which also enables quicker processing times. The use of automated technologies for the purification and analysis of nucleic acids is another development. Automation can help to lower expenses, boost efficiency, and decrease errors while also increasing accuracy. Additionally, by enhancing the scalability of nucleic acid manufacturing, these systems can let CDMOs generate vast amounts of nucleic acids for research or commercial purposes. Thus, driving the nucleic acid therapeutics market revenue. ## **Nucleic Acid Therapeutics Market Segment Insights:** ### **Nucleic Acid Therapeutics Product Insights** The Europe [Nucleic Acid Therapeutics](../../../reports/nucleic-acid-based-therapeutics-market-2978) market segmentation, based on product includes Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers, RNA interference [RNAi] and short interfering RNAs [siRNAs], and Others. The anti-sense oligonucleotides (ASOs) segment dominated the market mostly. Single-stranded, short RNA or DNA molecules known as antisense oligonucleotides (ASOs) can bind to specific messenger RNA (mRNA) sequences and either cause the targeted mRNA to decay or not translate into a protein. This property makes ASOs a potentially useful therapeutic strategy for a variety of conditions, including cancer, infectious illnesses, and genetic disorders. ### **Nucleic Acid Therapeutics Application Insights** The Europe Nucleic Acid Therapeutics market segmentation, based on application, includes Monogenetic Disorders and Multi-genetic Disorders. The monogenetic disorders category generated the most income due to the fact that the majority of diseases that are treated with nucleic acid therapies are hereditary and widespread. The release of recently developed and approved medicines for single [gene disorders](../../../reports/gene-therapy-market-8399) by major industry players is the main factor propelling the growth of the nucleic acid therapeutics market. Leading practitioners in the field are focusing on developing new strategies to deal with problems related to stability, gene quality, and off-targets in multi-genetic diseases. **Figure 1: Europe Nucleic Acid Therapeutics Market, by Application, 2022 & 2032 (USD Billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **Nucleic Acid Therapeutics End User Insights** The Europe Nucleic Acid Therapeutics market segmentation, based on end user, includes Hospitals and Clinics and Academic and Research Institutes. The hospitals and clinics category generated the most income. Customized medications are becoming more and more in demand as a result of the increased usage of treatments and vaccinations to address various chronic conditions. An additional factor driving this market segment is the rise in the number of visits to clinics and hospitals. ### **Nucleic Acid Therapeutics Regional Insights** The Europe nucleic acid therapeutics market area will grow at a significant rate due to the growing acceptance of innovative nucleic acid therapeutics and the accessibility of nucleic acid extraction technologies. The market expansion in this region is at its pinnacle and is anticipated to stay that way for the duration of the projected period because all favorable variables are present. Additionally, the growing investments in the healthcare industry have pushed research into the treatment of numerous illnesses and disorders. Furthermore, this area holds the largest share of the European nucleic acid therapies market due to the presence of multiple startups and established companies, as well as FDA approvals. **Figure 2: EUROPE NUCLEIC ACID THERAPEUTICS MARKET SHARE BY REGION 2022 (USD Billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Nucleic Acid Therapeutics Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the nucleic acid therapeutics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, nucleic acid therapeutics industry must offer cost-effective items. ### **Key Companies in the nucleic acid therapeutics market include** - [Sarpeta Therapeutics](https://www.sarepta.com/science/rna-platform) - Qaigen NV - Genzyme Sanofi - Copernicus - Merck KGaA - [Agilent Technologies](https://www.agilent.com/about/newsroom/presrel/2019/18jun-ca19017.html) - Protagonist Therapeutics - Thermo Fisher Scientific - NOVARTIS AG. - Benitec Biopharma - Silence Therapeutics - Arbutus Biopharma ## **Nucleic Acid Therapeutics Market Segmentation** ### **Nucleic Acid Therapeutics Products Outlook** - Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers - RNA interference [RNAi] and short interfering RNAs [siRNAs] - Others ### **Nucleic Acid Therapeutics Application Outlook** - Monogenetic disorders - Multi-genetic disorders ### **Nucleic Acid Therapeutics End User Outlook** - Hospitals and Clinics - Academic and Research Institutes ### **Nucleic Acid Therapeutics Regional Outlook** ## Market Drivers ### Supportive Regulatory Frameworks The Europe [Nucleic Acid Based Therapeutics](https://www.marketresearchfuture.com/reports/nucleic-acid-based-therapeutics-market-2978) Market is bolstered by a supportive regulatory environment that encourages innovation and expedites the approval process for new therapies. Regulatory bodies, such as the European Medicines Agency (EMA), have established clear guidelines for the development and commercialization of nucleic acid-based products. This regulatory clarity is essential for fostering investment and research in the sector. Moreover, the introduction of fast-track approval pathways for breakthrough therapies is likely to enhance the speed at which new treatments reach the market. As a result, companies are more inclined to invest in the development of nucleic acid therapeutics, knowing that there is a structured process in place to facilitate their entry into the market. ### Growing Investment in Biotechnology The increasing investment in biotechnology is a crucial driver for the Europe Nucleic Acid Based Therapeutics Market. Venture capital funding and public-private partnerships are on the rise, with significant financial resources being allocated to research and development in nucleic acid-based therapies. In 2025, investments in European biotech companies reached approximately 10 billion euros, reflecting a robust interest in innovative therapeutic solutions. This influx of capital is likely to accelerate the development of new nucleic acid-based treatments, as companies seek to capitalize on the growing demand for personalized medicine. The financial backing is expected to enhance collaboration between academic institutions and industry players, further propelling advancements in the market. ### Advancements in Delivery Technologies Innovations in delivery mechanisms for nucleic acid therapeutics are significantly influencing the Europe Nucleic Acid Based Therapeutics Market. Enhanced delivery systems, such as lipid nanoparticles and viral vectors, are improving the efficacy and safety profiles of these therapies. For instance, the successful application of lipid nanoparticles in mRNA vaccines has demonstrated the potential of these technologies in delivering nucleic acids effectively. As a result, the market is witnessing a surge in research focused on optimizing delivery methods, which could lead to more effective treatments for various diseases. The European market is expected to benefit from these advancements, as they may facilitate the broader adoption of nucleic acid-based therapies in clinical settings. ### Rising Demand for Personalized Medicine The shift towards personalized medicine is reshaping the Europe Nucleic Acid Based Therapeutics Market. Patients are increasingly seeking treatments tailored to their genetic profiles, which aligns with the capabilities of nucleic acid-based therapies. These therapies offer the potential for targeted treatment strategies, particularly in oncology and rare diseases. The European market is witnessing a growing trend towards the integration of genomic data into clinical practice, which may enhance the development of personalized nucleic acid therapeutics. As healthcare providers and patients alike recognize the benefits of personalized approaches, the demand for nucleic acid-based solutions is expected to rise, driving market growth in the coming years. ### Increasing Prevalence of Genetic Disorders The rising incidence of genetic disorders across Europe is a pivotal driver for the Europe Nucleic Acid Based Therapeutics Market. With an estimated 30 million individuals affected by rare diseases in the region, the demand for innovative therapies is surging. This growing patient population necessitates the development of nucleic acid-based treatments, such as gene therapies and RNA-based therapeutics, to address unmet medical needs. Furthermore, the European Union has implemented various initiatives to support research and development in this field, which may further stimulate market growth. The increasing awareness and diagnosis of genetic disorders are likely to propel investments in nucleic acid-based solutions, thereby enhancing the overall market landscape. ## Future Outlook The Europe Nucleic Acid Based Therapeutics Market is projected to grow at a 3.74% CAGR from 2025 to 2035, driven by advancements in gene editing and increasing prevalence of genetic disorders. **New opportunities:** - Development of personalized mRNA vaccines for infectious diseases Expansion of CRISPR-based therapies for rare genetic disorders Investment in automated nucleic acid synthesis platforms for cost reduction By 2035, the market is expected to be robust, driven by innovation and strategic investments. ## Segment Insights ### By Application: Oncology (Largest) vs. Genetic Disorders (Fastest-Growing) In the Europe Nucleic Acid Based Therapeutics Market, Oncology currently represents the largest application segment, capturing a significant share of market interest. This dominance is driven by increasing incidences of various cancers in the region and a rising preference for targeted therapies that leverage nucleic acid technologies. Following closely is the Genetic Disorders segment, which is rapidly gaining traction as more therapies targeting rare and inherited conditions are being developed and approved for use in European markets. Oncology (Dominant) vs. Genetic Disorders (Emerging) Oncology stands out as a dominant application in the Europe Nucleic Acid Based Therapeutics Market, benefiting from strong investments in research and development focused on cancer treatment methodologies. This segment encompasses a wide range of therapies that utilize nucleic acids to effectively target and modify cancer cells. In contrast, the Genetic Disorders segment is emerging quickly as the industry acknowledges the possibilities of [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) to address various inherited conditions. The surge in genetic research, coupled with increasing regulatory support for gene-editing technologies, makes this segment poised for significant future growth as it strives to address the unmet medical needs of patients with rare genetic conditions. ### By Technology: RNA Interference (Largest) vs. CRISPR (Fastest-Growing) The Europe Nucleic Acid Based Therapeutics Market is largely dominated by the RNA Interference (RNAi) segment, which holds a significant portion of the market share. RNAi technologies enable the silencing of specific genes, thereby offering a potent approach for treating various genetic disorders. Following closely is CRISPR technology, which, while currently smaller in share, is rapidly gaining traction among major stakeholders due to its flexibility and precision in [gene editing](https://www.marketresearchfuture.com/reports/gene-editing-market-707), making it an attractive option for new therapeutics. Technology: RNA Interference (Dominant) vs. CRISPR (Emerging) RNA Interference (RNAi) has established itself as the dominant technology in the Europe Nucleic Acid Based Therapeutics Market. It allows for targeted gene silencing, making it particularly effective for illnesses caused by defective genes. The established clinical pipelines and robust research backing its efficacy have solidified its market position. In contrast, CRISPR technology is viewed as an emerging powerhouse, with its ability to edit genes at precise locations offering new avenues for treatment. Its rapid advancements and successful trials in various applications are driving its increasing adoption, making it a key player for future growth within the sector. ### By Route of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) The Europe Nucleic Acid Based Therapeutics Market exhibits a varied distribution of market share across different routes of administration. Intravenous (IV) administration stands as the largest segment due to its effectiveness in delivering high concentrations of therapeutics directly into the bloodstream, resulting in rapid therapeutic action. In contrast, Subcutaneous (SC) administration is gaining traction, primarily driven by its convenience and ease of self-administration, appealing to both healthcare providers and patients alike. Intravenous (Dominant) vs. Subcutaneous (Emerging) Intravenous (IV) administration is regarded as the dominant route in the Europe Nucleic Acid Based Therapeutics Market due to its rapid onset and ability to administer larger doses effectively. This method is especially favored in clinical settings for its reliability and immediate action. Conversely, Subcutaneous (SC) administration is emerging as a significant player, offering several advantages, including a simple self-administration process and improved patient compliance. The trend towards SC routes is propelled by the growing demand for at-home therapies, which align with the increasing focus on patient-centric care. Both these routes are shaping the future landscape of nucleic acid therapies in Europe. ## Regional Market Share Analysis ### Germany : Strong Innovation and Investment Climate Germany holds a commanding 45.0% market share in the Nucleic Acid Based Therapeutics sector, driven by robust R&D investments and a strong healthcare infrastructure. The demand for personalized medicine and advanced therapies is surging, supported by government initiatives promoting biotech innovation. Regulatory frameworks are favorable, with agencies like the Paul-Ehrlich-Institut facilitating swift approvals for new therapies, enhancing market growth. ### UK : Strong Research and Development Focus The UK commands a 30.0% share in the Nucleic Acid Based Therapeutics market, bolstered by a vibrant biotech ecosystem centered in cities like Cambridge and London. Key growth drivers include significant public and private investments in R&D, alongside a favorable regulatory environment post-Brexit. The demand for gene therapies is rising, with the NHS actively integrating innovative treatments into its healthcare offerings. ### France : Government Support and Innovation France holds a 25.0% market share in the Nucleic Acid Based Therapeutics sector, driven by strong government support for biotech initiatives. The French government has launched several programs to enhance R&D funding, particularly in Paris and Lyon, where many biotech firms are located. Regulatory bodies like the ANSM are streamlining approval processes, fostering a conducive environment for innovation and market entry. ### Russia : Investment in Healthcare Infrastructure Russia's Nucleic Acid Based Therapeutics market accounts for 20.0% of the European share, with increasing investments in healthcare infrastructure. The government is prioritizing biotechnology as part of its national strategy, aiming to enhance local production capabilities. However, regulatory hurdles and market access issues remain challenges, impacting the speed of innovation and adoption of new therapies. ### Italy : Focus on Research and Development Italy represents 18.0% of the Nucleic Acid Based Therapeutics market, with a growing emphasis on R&D in regions like Lombardy and Emilia-Romagna. The Italian government is investing in biotech through initiatives that support clinical trials and innovation. Local companies are increasingly collaborating with international firms, enhancing the competitive landscape and driving demand for advanced therapies. ### Spain : Investment in Biotech Innovation Spain holds a 10.0% share in the Nucleic Acid Based Therapeutics market, with significant growth potential driven by increased investment in biotech research. Cities like Barcelona and Madrid are becoming hubs for innovation, supported by government initiatives aimed at fostering collaboration between academia and industry. Regulatory bodies are working to streamline processes, enhancing market accessibility for new therapies. ### Rest of Europe : Varied Growth Opportunities Across Regions The Rest of Europe accounts for 8.18% of the Nucleic Acid Based Therapeutics market, encompassing a diverse range of countries with varying market dynamics. Growth is driven by localized demand for innovative therapies and supportive government policies in countries like Belgium and the Netherlands. However, regulatory environments differ significantly, impacting market entry and competition. ## Competitive Benchmarking The Nucleic Acid Based Therapeutics Market in Europe is characterized by a dynamic competitive landscape, driven by rapid advancements in genetic research and increasing investments in biopharmaceutical innovations. Key players such as Roche (CH), Novartis (CH), and BioNTech (DE) are at the forefront, leveraging their extensive research capabilities and strategic partnerships to enhance their market positioning. Roche (CH) focuses on integrating cutting-edge technologies into its therapeutic development processes, while Novartis (CH) emphasizes a robust pipeline of RNA-based therapies, indicating a strong commitment to innovation. BioNTech (DE), known for its mRNA technology, continues to expand its applications beyond infectious diseases, suggesting a strategic pivot towards oncology and rare diseases, thereby shaping a competitive environment that prioritizes innovation and therapeutic diversity. In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. The market structure appears moderately fragmented, with a mix of established players and emerging biotech firms. This fragmentation allows for a diverse range of therapeutic options, although the collective influence of major players like AstraZeneca (GB) and GSK (GB) remains significant, as they continue to invest heavily in R&D and strategic collaborations. In December 2025, Roche (CH) announced a partnership with a leading European biotech firm to co-develop a novel RNA-based therapeutic for rare genetic disorders. This collaboration is poised to enhance Roche's portfolio and underscores its commitment to addressing unmet medical needs. The strategic importance of this partnership lies in its potential to accelerate the development timeline and broaden access to innovative treatments in niche markets. In November 2025, Novartis (CH) revealed a significant investment in a new manufacturing facility in Switzerland dedicated to the production of gene therapies. This move not only aims to streamline production processes but also reflects Novartis's long-term strategy to solidify its leadership in the gene therapy space. The establishment of this facility is likely to enhance operational efficiency and support the growing demand for advanced therapeutics. In October 2025, BioNTech (DE) expanded its collaboration with a prominent academic institution to explore the use of mRNA technology in personalized [cancer vaccines](https://www.marketresearchfuture.com/reports/cancer-vaccine-market-9087). This initiative highlights BioNTech's strategic focus on harnessing its proprietary technology to develop tailored therapies, which could significantly impact treatment outcomes in oncology. The emphasis on personalized medicine aligns with current trends towards individualized patient care, potentially setting a new standard in cancer treatment. As of January 2026, the competitive trends in the Nucleic Acid Based Therapeutics Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex healthcare challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative therapeutic solutions, and reliable supply chains, thereby reshaping the market landscape. ## Report Scope | MARKET SIZE 2024 | 156.18(USD Million) | | --- | --- | | MARKET SIZE 2025 | 162.62(USD Million) | | MARKET SIZE 2035 | 233.87(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.74% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche (CH), Novartis (CH), Sanofi (FR), Bayer (DE), AstraZeneca (GB), GSK (GB), BioNTech (DE), CureVac (DE), Genmab (DK) | | Segments Covered | Application, Technology, Route of Administration | | Key Market Opportunities | Advancements in gene editing technologies drive growth in the Europe Nucleic Acid Based Therapeutics Market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in Europe's Nucleic Acid Based Therapeutics Market. | | Countries Covered | Germany, UK, France, Russia, Italy, Spain, Rest of Europe | ## Frequently Asked Questions **Q: What is the current valuation of the Europe Nucleic Acid Based Therapeutics Market?** A: As of 2024, the market valuation was 156.18 USD Million. **Q: What is the projected market valuation for the Europe Nucleic Acid Based Therapeutics Market in 2035?** A: The market is projected to reach 233.87 USD Million by 2035. **Q: What is the expected CAGR for the Europe Nucleic Acid Based Therapeutics Market during the forecast period?** A: The expected CAGR for the market from 2025 to 2035 is 3.74%. **Q: Which applications dominate the Europe Nucleic Acid Based Therapeutics Market?** A: Oncology, Genetic Disorders, and Neurological Disorders are key applications, with valuations of 40.0 to 60.0, 30.0 to 50.0, and 41.18 to 53.87 USD Million, respectively. **Q: What are the leading technologies in the Europe Nucleic Acid Based Therapeutics Market?** A: Gene Therapy and RNA Interference are leading technologies, with projected valuations of 50.0 to 80.0 and 30.0 to 45.0 USD Million, respectively. **Q: How does the route of administration impact the market segments?** A: Oral and Intravenous routes are significant, with valuations ranging from 40.0 to 60.0 and 39.0 to 58.0 USD Million, respectively. **Q: Who are the key players in the Europe Nucleic Acid Based Therapeutics Market?** A: Key players include Roche, Novartis, Sanofi, Bayer, AstraZeneca, GSK, BioNTech, CureVac, and Genmab. **Q: What is the market performance for infectious diseases within the nucleic acid therapeutics segment?** A: The market for infectious diseases was valued between 25.0 and 40.0 USD Million. **Q: What is the valuation range for cardiovascular diseases in the market?** A: Cardiovascular diseases are valued between 20.0 and 30.0 USD Million in the market. **Q: How does the market for antisense oligonucleotides compare to other technologies?** A: Antisense oligonucleotides are valued between 25.0 and 35.0 USD Million, indicating a competitive position among other technologies. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/europe-nucleic-acid-therapeutics-market-12660*